|
1) Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006; 130: 1466-79
|
|
|
|
|
2) Caldarella MP, Azpiroz F, Malagelada JR. Antro-fundic dysfunctions in functional dyspepsia. Gastroenterology. 2003; 124: 1220-9
|
|
|
|
|
|
3) Delgado-Aros S, Camilleri M, Cremonini F, et al. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology. 2004; 127: 1685-94
|
|
|
|
|
|
4) Tack J, Lee KJ. Pathophysiology and treatment of functional dyspepsia. J Clin Gastroenterol. 2005; 39 (Suppl 3): S211-6
|
|
|
|
|
5) Kusano M, Zai H, Shimoyama Y, et al. Rapid gastric empting, rather than delayed gastric empting, might provoke functional dyspepsia. J Gastroenterol Hepatol. 2011; 28: 1440-746
|
|
|
|
|
|
6) Miwa H, Nakajima K. Generation of dyspeptic symptoms by direct acid infusion into the stomach of healthy Japanese subjects. Aliment Pharmacol Ther. 2007; 15; 26: 257-64
|
|
|
|
|
|
7) Lee KJ, Demarci B, Demedts I, et al. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol. 2004; 99: 1765-73
|
|
|
|
|
|
8) 武田宏司, 武藤修一, 服部智久, 他. FDに対する漢方薬の効果と脳腸相関, 心身医学. 2009; 49: 807-13
|
|
|
|
|
9) Holtmann G, Siffertw, Haag S, et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained(functional) dyspepsia. Gastroenterology. 2004; 126: 971-9
|
|
|
|
|
|
10) Tahara T, Arisawa T, Shibata T, et al. Homozygous 825T allele of the GNB3 protein influences the susceptibility Japanese to dyspepsia. Dig Dis Sci. 2008; 53: 642-6
|
|
|
|
|
|
11) Tahara T, Shibata T, Nakamura T, et al. Homozygous TRPV1 315C influences the susceptibility to functional dyspepsia. J Clin Gastroenterol. 2010; 44: e1-7
|
|
|
|
|
|
12) Chen CY, Asakawa A, Fujimiya M, et al. Ghrelin gene products and the regulation of food intake and gut motility. Pharmacol Rev. 2009; 61: 430-81
|
|
|
|
|
|
13) Suzuki H, Hibi T. Acotiamide(Z-338) as a possible candidate for the treatment of functional dyspepsia. Neurogastroenterol Motil. 2010; 22: 595-9
|
|
|
|
|
|
14) Tack J, Janssen P. Emerging drugs for functional dyspepsia. Expert Opin Emerg Drugs. 2011; 16: 283-92
|
|
|
|
|
|
15) Tack J, Janssen P. Acotiamide(Z-338, YM443), a new dtug for the treatment of functional dyspepsia. Expert Opin Investig Drugs. 2011; 20: 701-12
|
|
|
|
|
|
16) Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome Ⅲ classification. J Gastroenterol. 2006; 41: 513-23
|
|
|
|
|
|
17) Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobactor pylori for nonulcer dyspepsia. Cochrane Database Syst Rev. 2006: CD002096
|
|
|
|
|
|
18) Tominaga K, Higuchi K, Iketani T, et al. Comparison of gastrointestinal symptoms and psychological factors of functional dyspepsia to peptic ulcer or panic disorders patients. Inflammopharmacology. 2007; 15: 84-9
|
|
|
|
|
|
19) Camilleri CE, Carlson PJ, Camilleri M, et al. A study of candidate genotypes associated with dyspepsia in a US community. Am J Gastroenterol. 2006; 101: 581-92
|
|
|
|
|
|
20) Baumgurt D, Naber C, Haude M, et al. G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation. Cric Res. 1999; 85: 965-9
|
|
|
|
|
|
21) Arisawa T, Tahara T, Shibata T, et al. Genetic polymorphism of molecules associated with inflammation and immune response in Japanese subject with functional dyspepsia. Int J Mol Med. 2007; 20: 717-23
|
|
|
|
|
|
22) Tahara T, Shibata T, Wang K, et al. A genetic variant of the p22PHOX component of NADPH oxidase C242T is associated with reduced risk of functional dyspepsia in Helicobacter pylori infected Japanese individuals. Eur J Gastroenterol Hepatol. 2009; 21: 1363-8
|
|
|
|
|
|
23) Tahara T, Shibata T, Yamashita H, et al. The role of RANTES promoter polymorphism in functional dyspepsia. J Clin Biochem Nutr. 2009; 45: 235-40
|
|
|
|
|
24) Oshima T, Toyoshima F, Nakajima S, et al. Genetic factors for functional dyspepsia. J Gastroenterol Hepatol. 2011; 26: 1440-1746
|
|
|
|
|
|
25) Arisawa T, Tahara T, Shibata T, et al. Genetic polymorphisms of cyclooxygenase-1(COX-1) are associated with functional dyspepsia in Japanese woman. J Womans Haelth. 2008; 17: 1039-43
|
|
|
|
|
|
26) Hanevik K, Hausken T, Morken MH, et al. Persisting symptoms and duodenal inflammation related to Giardia duodenalis infection. J Infect. 2007; 55: 524-30
|
|
|
|
|
|
27) Dizdar V, Gilja OH, Hausken T. Increased visceral sensivity in Gialjia-induced postinfectous irritable bowel syndrome and functional dyspepsia. Effect of the 5HT(3) 1-antagonist ondansetron. Neurogastroenterol Motil. 2007; 19: 977-82
|
|
|
|
|
|
28) Dizdar V, Spiller R, Singh G, et al. Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2010 Feb 2[Epub ahead of print]
|
|
|
|
|
|
29) Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow up study. Gastrosnterology. 2005; 129: 98-104
|
|
|
|
|
|
30) Ji S, Park H, Lee D, et al. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatorol. 2005; 20: 381-6
|
|
|
|
|
|
31) Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophilis and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010; 105: 1835-42
|
|
|
|
|
|
32) Talley NJ, Vakil N. Guide lines for the management of dyspepsia. Am J Gastroenterol. 2005; 100: 2324-37
|
|
|
|
|
|
33) Tack J, Talley NJ. Gastroduodenal disorders. Am J Gastroenterol. 2010; 105: 757-63
|
|
|
|
|
|
34) Geeraerts B, Tack J. Functional dyspepsia: past, present, and future. J Gastroenterol. 2008; 43: 251-5
|
|
|
|
|
|
35) Moyyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobactor pylori eradication treatment for non-ulcer dyspepsia. BMJ. 2000; 321: 659-64
|
|
|
|
|
|
36) 日本ヘリコバクター学会ガイドライン作成委員会. H. pylori 感染の診断と治療のガイドライン1. 2009改訂版. 日本ヘリコバクター学会誌. 2009; 10: 104-28
|
|
|
|
|
|
37) Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht Ⅲ Consensus Report. Gut. 2007; 56: 772-81
|
|
|
|
|
|
38) Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia. Aliment Pharmacol Ther. 2006; 24: 49-57
|
|
|
|
|
|
39) 松田和也, 山本佳洋, 鳥居 明. ROMEⅢに準じたFunctional Dyspepsia患者に対するH2受容体拮抗薬ニザチジンの胃炎用量における有用性の検討. Ther Res. 2010; 31: 899-904
|
|
|
|
|
40) Suzuki H, Inadomi JM, Hibi T. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil. 2009; 21: 688-96
|
|
|
|
|
|
41) Tominaga K, Kido T, Ochi M, et al. The traditional Japanese medicine Rikkunshito promotes gastric empting via the antagonistic action of the 5-HT3 receptor pathway in rats. Evid Based Component Alternat Med. 2009; 27[Epub ahead of the print]
|
|
|
|
|
|
42) Takada H, Sadakane C, Hattori T, et al. Rikkunnshito, an herbal medicine, superpress cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology. 2008; 134: 2004-13
|
|
|
|
|
|
43) Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010; 151: 3773-82
|
|
|
|
|
|
44) Fujitsuka N, Asakawa A, Hayashi M, et al. Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrerin. Biol Psychiatry. 2009; 65: 748-59
|
|
|
|
|
|
45) Hojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxietry or antidepressive agent: systematic review. J Gastroenterol. 2005; 40: 1036-42
|
|
|
|
|